Orient Pharma Co's total inventories for the quarter that ended in Dec. 2025 was NT$322 Mil. Orient Pharma Co's average total inventories from the quarter that ended in Sep. 2025 to the quarter that ended in Dec. 2025 was NT$337 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Orient Pharma Co's Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was NT$2.39.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Orient Pharma Co's Days Inventory for the
three
months ended in Dec. 2025 was 174.59.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Orient Pharma Co's Inventory Turnover for the quarter that ended in Dec. 2025 was 0.52.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Orient Pharma Co's Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 0.76.
Orient Pharma Co (ROCO:4166) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Orient Pharma Co's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Orient Pharma Co's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Orient Pharma Co Total Inventories Related Terms
Orient Pharma Co Total Inventories Historical Data
* Premium members only.
The historical data trend for Orient Pharma Co's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Orient Pharma Co (ROCO:4166) has a Total Inventories of NT$322 Mil as of Dec. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for Orient Pharma Co and its competitors.
Is Orient Pharma Co's Total Inventories too high?
Orient Pharma Co's current Total Inventories is NT$322 Mil. Overall, Orient Pharma Co has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orient Pharma Co's Total Inventories compare to ZTS and UTHR?
Orient Pharma Co's Total Inventories of NT$322 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Drug Manufacturers company?
A good Total Inventories depends on the Drug Manufacturers industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Orient Pharma Co and its competitors. Orient Pharma Co's current Total Inventories is NT$322 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orient Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Orient Pharma Co (ROCO:4166) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$45.09, compared to a current price of NT$27.20 — trading 39.7% below its estimated fair value. The current Total Inventories is NT$322 Mil. Orient Pharma Co's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Orient Pharma Co (ROCO:4166), the current Total Inventories is NT$322 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orient Pharma Co (ROCO:4166) Overvalued in 2026?
Based on GuruFocus' analysis, Orient Pharma Co stock appears to be undervalued.
The current stock price of NT$27.20 is trading 39.7% below its estimated GF Value™ of NT$45.09.
GuruFocus considers Orient Pharma Co to be Significantly Undervalued.
Key valuation signals for ROCO:4166:
Total Inventories: NT$322 Mil
GF Value™: NT$45.09 vs. price of NT$27.20 (39.7% below fair value)
No single metric tells the full story. See the ROCO:4166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orient Pharma Co Ltd develops and manufactures pharmaceuticals. The Company mainly engages in the manufacturing, wholesale, and retail of western medicine and medical devices, as well as international trade. The company has two operating segments-Taiwan business segment- mainly engaged in developing the Taiwan pharmaceutical market and conducting related business activities and the other segment is Overseas business segment -mainly engaged in developing potential overseas pharmaceutical markets. Company's products include Cardiovascular drugs and Psychotropic drugs. The Group mainly operates in four regions: Taiwan, the United States, the Philippines, and China generating key revenue from Taiwan.
56GF Score
Get the complete analysis for ROCO:4166
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4166 has been successfully added to your 
